Talopram

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584801

CAS#: 7182-51-6

Description: Talopram is a putative PET ligand for the norepinephrine transporter.


Chemical Structure

img
Talopram
CAS# 7182-51-6

Theoretical Analysis

MedKoo Cat#: 584801
Name: Talopram
CAS#: 7182-51-6
Chemical Formula: C20H25NO
Exact Mass: 295.19
Molecular Weight: 295.426
Elemental Analysis: C, 81.31; H, 8.53; N, 4.74; O, 5.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Talopram; Phthalapromine; Talopramum; Talopran

IUPAC/Chemical Name: N,3,3-Trimethyl-1-phenyl-1-phthalanpropylamin

InChi Key: LJBBMCNHIUJBDU-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H25NO/c1-19(2)17-12-7-8-13-18(17)20(22-19,14-9-15-21-3)16-10-5-4-6-11-16/h4-8,10-13,21H,9,14-15H2,1-3H3

SMILES Code: CC1(C)OC(CCCNC)(C2=CC=CC=C2)C3=CC=CC=C13

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 295.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schou M, Sóvágó J, Pike VW, Gulyás B, Bøgesø KP, Farde L, Halldin C. Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram. Mol Imaging Biol. 2006 Jan-Feb;8(1):1-8. PubMed PMID: 16322935.

2: Eildal JN, Andersen J, Kristensen AS, Jørgensen AM, Bang-Andersen B, Jørgensen M, Strømgaard K. From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem. 2008 May 22;51(10):3045-8. doi: 10.1021/jm701602g. Epub 2008 Apr 23. PubMed PMID: 18429609.

3: McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Camp VM, Votaw JR, Nemeroff CB, Goodman MM. Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nucl Med Biol. 2004 Aug;31(6):705-18. PubMed PMID: 15246361.

4: Larsen MA, Plenge P, Andersen J, Eildal JN, Kristensen AS, Bøgesø KP, Gether U, Strømgaard K, Bang-Andersen B, Loland CJ. Structure-activity relationship studies of citalopram derivatives: examining substituents conferring selectivity for the allosteric site in the 5-HT transporter. Br J Pharmacol. 2016 Mar;173(5):925-36. doi: 10.1111/bph.13411. Epub 2016 Feb 8. PubMed PMID: 26699847; PubMed Central PMCID: PMC4761100.

5: Stadaas JO, Aune S, Petersen H. The effect of phthalapromine and prindamine on gastric motility. Scand J Gastroenterol Suppl. 1976;42:127-8. PubMed PMID: 796965.

6: Stadaas J, Aune S. The effect of phthalapromine (LU 3-010) on gastric motility in man. Scand J Gastroenterol. 1971;6(1):23-7. PubMed PMID: 5100065.

7: Andersen J, Stuhr-Hansen N, Zachariassen L, Toubro S, Hansen SM, Eildal JN, Bond AD, Bøgesø KP, Bang-Andersen B, Kristensen AS, Strømgaard K. Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12137-42. doi: 10.1073/pnas.1103060108. Epub 2011 Jul 5. PubMed PMID: 21730142; PubMed Central PMCID: PMC3141962.

8: Zheng G, Yang F, Fu T, Tu G, Chen Y, Yao X, Xue W, Zhu F. Computational characterization of the selective inhibition of human norepinephrine and serotonin transporters by an escitalopram scaffold. Phys Chem Chem Phys. 2018 Nov 28;20(46):29513-29527. doi: 10.1039/c8cp06232c. PubMed PMID: 30457616.

9: Ding YS, Lin KS, Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des. 2006;12(30):3831-45. Review. PubMed PMID: 17073682.

10: Dell'Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. J Clin Psychiatry. 2008 Mar;69(3):452-6. PubMed PMID: 18312057.

11: Olsen CK, Hogg S, Lapiz MD. Tonic immobility in guinea pigs: a behavioural response for detecting an anxiolytic-like effect? Behav Pharmacol. 2002 Jul;13(4):261-9. PubMed PMID: 12218506.

12: Maxwell RA, Ferris RM, Woodward EC, Tang FL, Eckhardt SB. Structure-activity relationships for potent phthalane and thiophthalane inhibitors of norepinephrine uptake. A comparison with desipramine and related compounds. Mol Pharmacol. 1980 May;17(3):321-7. PubMed PMID: 7393212.

13: Falkin L, Varon D, Erez M, Neuman M, Manoach M, Bøgesø KP. The defibrillating effect of catecholamine reuptake inhibitors. J Basic Clin Physiol Pharmacol. 1993 Oct-Dec;4(4):291-7. PubMed PMID: 8664246.

14: Bauer VJ, Duffy BJ, Hoffman D, Klioze SS, Kosley RW Jr, McFadden AR, Martin LL, Ong HH. Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. J Med Chem. 1976 Nov;19(11):1315-24. PubMed PMID: 1003409.

15: Hedner J, Almgren O, Jonason J, Lundberg D. Neuronal and extraneuronal uptake of 3H-noradrenaline in rat portal vein in vitro. Acta Physiol Scand. 1981 Feb;111(2):171-7. PubMed PMID: 7282392.

16: Nilsson H, Sjöblom N, Folkow B. Interaction between prejunctional alpha 2-receptors and neuronal transmitter reuptake in small mesenteric arteries from the rat. Acta Physiol Scand. 1985 Oct;125(2):245-52. PubMed PMID: 2866662.